Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350543 | 0.80 | ALDH1A1 (0.53) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL6748588 | 0.79 | ALOX5 (0.50) | MAPTKDM4EHPGDALDH1A1TSHR | |
| SCHEMBL998182 | 0.78 | MAPT (1.00) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL29428410 | 0.78 | MAPT (1.00) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL6313018 | 0.77 | MAPT (0.50) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL30380487 | 0.77 | MAPT (0.67) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL278576 | 0.77 | MAPT (0.67) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL25205 | 0.77 | MAPT (0.67) | MAPTNQO1KDM4EHPGDMEN1 | |
| SCHEMBL7654717 | 0.76 | MAPT (0.46) | MAPTKDM4EKMT2AALDH1A1CYP2A6 | |
| SCHEMBL8518991 | 0.76 | CA12 (0.52) | MAPTNQO1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | claimed |
| US-9470680-B2 | Fluorescence-based approach to monitor release factor-catalyzed termination of protein synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-18 | — | — | US | disclosed |
| EP-1543329-B1 | CELL-BASED FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ASSAYS FOR CLOSTRIDIAL TOXINS | ALLERGAN INC (US) | 2016-08-03 | — | — | EP | disclosed |
| CN-101686665-B | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2014-04-23 | — | — | CN | disclosed |
| US-20130034914-A1 | FLUORESCENCE-BASED APPROACH TO MONITOR RELEASE FACTOR-CATALYZED TERMINATION OF PROTEIN SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-02-07 | — | — | US | disclosed |
| EP-1438586-B1 | FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS | ALLERGAN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1901069-B1 | Fret protease assays for clostridial toxins | ALLERGAN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8053208-B2 | FRET protease assays for clostridial toxins | ALLERGAN, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053209-B2 | FRET protease assays for clostridial toxins | ALLERGAN, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048643-B2 | FRET protease assays for clostridial toxins | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999011655-A1 | MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION | GRYPHON SCIENCES (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| CN-1036064-C | Benzene derivatives having NGF production-promoting activity | SANKYO CO (JP) | 1997-10-08 | — | — | CN | disclosed |
| US-5643925-A | COGNITION ACTIVATORS AND NERVE GROWTH FACTORS | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5614521-A | NERVE GROWTH FACTOR | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0501656-B1 | New benzene derivatives having (NGF) production-promoting activity | SANKYO CO (JP) | 1997-01-22 | — | — | EP | disclosed |
| CN-1064273-A | The new NGF that has generates the active benzene derivative of promotion | SANKYO CO (JP) | 1992-09-09 | — | — | CN | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4276305-A | INSECTICIDES, MITICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | NMT2, NMT1, MBOAT1 | MAPT 133/4885NQO1 3265/4885KDM4E 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.